AI Article Synopsis
- Recent studies suggest that CD103 T cells play a role in antitumor immunity in gastric cancer, but their significance in Borrmann type 4 gastric cancer (GC) is not well understood.
- Tissue samples from 46 patients with type 4 GC were analyzed using immunohistochemical staining to assess CD103 T cell presence.
- Patients with high CD103 expression showed better prognosis, especially those who underwent doublet chemotherapy post-surgery, indicating that CD103 T cells could be a potential prognostic marker in type 4 GC.
Article Abstract
Background/aim: Recently, several studies have reported that CD103 T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 T cells with type 4 GC.
Materials And Methods: Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 T cells.
Results: A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis.
Conclusion: CD103 T cells may be a prognostic marker in type 4 GC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066542 | PMC |
| http://dx.doi.org/10.21873/cdp.10121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!